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Abstract
Celiac disease (CD) is a unique autoimmune disorder in which the genetic factors (DQ2/DQ8) and the environmental trigger
(gluten) are known and necessary but not sufficient for its development. Other environmental components contributing to
CD are poorly understood. Studies suggest that aspects of gluten intake might influence the risk of CD occurrence and
timing of its onset, i.e., the amount and quality of ingested gluten, together with the pattern of infant feeding and the age
at which gluten is introduced in the diet. In this study, we hypothesize that the intestinal microbiota as a whole rather than
specific infections dictates the switch from tolerance to immune response in genetically susceptible individuals. Using a
sample of infants genetically at risk of CD, we characterized the longitudinal changes in the microbial communities that
colonize infants from birth to 24 months and the impact of two patterns of gluten introduction (early vs. late) on the gut
microbiota and metabolome, and the switch from gluten tolerance to immune response, including onset of CD
autoimmunity. We show that infants genetically susceptible to CD who are exposed to gluten early mount an immune
response against gluten and develop CD autoimmunity more frequently than at-risk infants in which gluten exposure is
delayed until 12 months of age. The data, while derived from a relatively small number of subjects, suggest differences
between the developing microbiota of infants with genetic predisposition for CD and the microbiota from infants with a
non-selected genetic background, with an overall lack of bacteria of the phylum Bacteriodetes along with a high abundance
of Firmicutes and microbiota that do not resemble that of adults even at 2 years of age. Furthermore, metabolomics analysis
reveals potential biomarkers for the prediction of CD. This study constitutes a definite proof-of-principle that these
combined genomic and metabolomic approaches will be key to deciphering the role of the gut microbiota on CD onset.
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Introduction
Celiac disease (CD) is a unique autoimmune disorder in that
the key genetic components (HLA class II genes DQ2 and/or
DQ8) are present in almost the totality of patients, the auto-
antigen (tissue transglutaminase) has been identified, and, most
importantly, the environmental trigger (gluten) is known [1].
Incomplete gluten digestion by intraluminal enzymes, changes in
intestinal permeability and activation of innate immunity
mechanisms are integral parts of the CD pathogenesis and all
seem to precede the activation of the CD T-cell–mediated
adaptive immune response leading to the autoimmune insult [2].
CD is strongly associated with specific HLA class II genes known
as HLA-DQ2 and HLA-DQ8 located on chromosome 6p21. A
multitude of non-HLA genes contribute to the CD genetic
background, but each of them adds only a modest contribution to
the disease development [3].
Gluten, the major protein component of wheat, with similar
toxic proteins in rye and barley, represents the main environmen-
tal factor. The high proline content renders gluten proteins
resistant to complete proteolytic digestion, leading to the
accumulation of relatively large peptide fragments with a high
proline and glutamine content in the small intestine triggering
abnormal immune response in susceptible individuals [4]. The
response is cooperatively mediated by both the innate and the
adaptive immune systems. The adaptive response is due to gliadin-
reactive CD4+ T-cells with consequent production of proinflam-
matory cytokines and specific anti-tissue transglutaminase (tTG)
antibodies [5,6]. The innate immune response in the intestinal
epithelium is characterized by increased expression of interleukin-
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lymphocytes [7]. Furthermore, in CD, gluten causes CXCR3-
mediated release of zonulin [8], a protein that enhances intestinal
permeability by targeting the proteinase activator receptor 2 (PAR)
and subsequent transactivation of epidermal growth factor
receptor (EGFR) [9]. This loss of intestinal barrier function causes
the uncontrolled passage of gluten peptides and other environ-
mental antigens from the gut lumen to the lamina propria with
their subsequent exposure to the gastrointestinal immune system.
Detection of anti-gliadin antibodies (AGA) has been abandoned as
a test for CD diagnosis due to their poor specificity for the disease.
However, AGA of the class IgG has been previously reported as a
possible biomarker of increased intestinal permeability [10,11].
Long regarded as a gastrointestinal disorder of childhood, the
disease is now more often diagnosed in adults than in children
[12]. The reasons for this delayed onset of the disease remain
undefined. It has been speculated that loss of gluten tolerance
leading to immunological and mucosal changes typical of CD
usually develops early in life, soon after the exposure to the
environmental trigger (i.e., at weaning), while the onset of clinical
manifestations of the disease can appear much later [1]. However,
we have recently demonstrated that loss of gluten tolerance may
occur at any time in life for reasons that are currently unclear [13].
Several data suggest that many aspects of gluten intake might
influence the risk of CD occurrence and the timing of its onset, i.e.,
the amount and the quality of ingested gluten, together with the
pattern of infant feeding and the age at which gluten is introduced
in the diet. It is well established that infant nutrition in the first
year of life is critical, as derangements of tolerance to food antigens
can lead to food allergic disorders [14].
Still the environmental components other than gluten that favor
CD development are thought to be numerous and poorly
understood. Fewer than 10% of individuals with an increased
genetic susceptibility develop clinical disease and most of them
develop the condition many years after their first exposure to
gluten. This suggests that, beside gluten, other environmental
trigger(s) could be involved in the pre-autoimmune process.
Several mechanisms that could lead to development of a gluten
specific T-cell response have been proposed. For example, it is has
been hypothesized that molecular mimicry between the EIB
protein of adenovirus type 12 [15] or hyphal wall protein 1 of
Candida albicans [16] and gluten could act as major factors that
trigger the disease, but this remains speculative. It has been also
proposed that a high frequency of rotavirus infections increases the
risk of CD in childhood in genetically predisposed individuals [17].
The increased production of IFN-c in anti-enteroviral immunity
would lead to a shift toward Th1 responses leading to loss of
tolerance for gluten [18]. Similarly, it has been postulated that the
GI tract microbiota may play a major role in the pathogenesis of
CD. For example, rod-shaped bacteria were frequently associated
with the mucosa in CD patients, with both active and inactive
disease, but not in controls [19], however a direct role for these
bacteria or any others in disease development has not been
established. Although intestinal infections might explain the break
of tolerance in children, their role in the development of late and
adult onset CD is less convincing. Nevertheless, in this study, we
hypothesize that the intestinal microbial ecosystem as a whole
rather than specific infections dictates the switch from tolerance to
immune response in genetically susceptible individuals. However,
at present, little is known about the potential role of the gut
microbiota in CD. Compared to healthy individuals, adults or
children with CD seem to be characterized by a somewhat
different composition of the gut microbiota [20,21,22,23,24,25].
Differences in microbial metabolites between fecal samples of CD
patients and healthy controls point to a functional role of the
microbiota in the pathogenesis of CD [22,25,26]. A significantly
higher number of Gram-negative and potentially pro-inflamma-
tory bacteria was found to be associated with the symptomatic
presentation of CD [23]. The unbalanced microbiota in children
with untreated CD seems only partially restored after long-term
treatment with a gluten free diet [20,24].
In the present study, we characterized the longitudinal changes
from birth to 24 months of age in the microbial communities that
colonize infants genetically at risk of CD and the impact of two
different patterns of gluten introduction (early vs. late) on the gut
microbiota, the fecal metabolome, and the switch from gluten
tolerance to immune response, including onset of CD autoimmu-
nity. For the first time, a combination of high-resolution culture-
independent methods based on pyrosequencing of barcoded 16S
rRNA gene amplicons, quantitative PCR, and metabolomic
analysis was used to determine the composition and temporal
changes of the gut microbiota as well as to identify potential
metabolomic biomarkers associated with onset of CD in these at-
risk infants. This study constitutes a definite proof-of-principle that
these combined genomic approaches will be key to deciphering the
role of the gut microbiota on CD onset.
Results
Subject enrollment
Forty-seven infants, first-degree relatives of patients with biopsy-
proven CD, were enrolled before weaning (between birth and 6
months of age) (Table S1). It is noteworthy that all infants
enrolled in this study were breastfed from birth to at least until 6
months of age (range 6 m–10 m, Table S2). A total of 34 infants
were positive for HLA DQ2 and/or HLA DQ8 genotypes and
fulfilled the inclusion criteria. From 6 to 12 months of age these
infants were randomized to either a gluten-free diet (delayed
exposure group A) or a gluten-containing diet (early exposure
group B). At 12 months of age, they resumed a normal diet. A total
of 13 infants in each group completed the protocol (for more
details, see materials and methods section). Collected clinical data,
including type of delivery, gestational age, weight, type of feeding
and neonatal problems, are shown in Table S1.
For feasibility reasons, a subgroup of 8 infants in each group was
randomly selected to perform microbiota and metabolome
analysis. A total of 96 stool samples from these 16 babies were
collected up to 24 months of age (Table S2). On average, 6
samples (range 3–8) were collected longitudinally from each
subject spanning 8 different time points (7 and 30 days, 6, 8, 10,
12, 18 and 24 months).
Celiac disease development and serologic evaluation
None of the eight babies in group A developed CD as defined
by the appearance of CD anti-TTG antibodies, the onset of CD-
related symptoms, and/or evidence of autoimmune enteropathy.
One out of eight babies (12.5%) in group B developed CD at 24
months of age (AGA IgA 55.2 U/ml, AGA IgG 26.3 U/ml, anti-
tTG IgG 51.9 U/ml, EMA IgA.1:20) and started a gluten-free
diet with subsequent normalization of serological tests at the follow
up visit (outside of the clinical study).
The comparison of AGA IgG positivity development over time
in the two groups and its cumulative incidence are shown in
Table S3 and Figure 1. After normalizing the two groups by
time of gluten exposure, the comparison shows a higher number of
AGA IgG positivity in group B (Figure 1). These results suggest
that early exposure to gluten in at-risk infants is associated with
increased gut permeability to the protein in the intestinal lamina
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gluten as testified by the IgG class of the AGA detected.
Characterization of HLA DQ2
+/DQ8
+ infant gut
microbiota from day 7 to 24 months of age
To characterize the succession of bacterial taxa that colonize the
GI microbiota of DQ2
+ and/or DQ8
+ infants from 7 days to 24
months of age, we used pyrosequencing of barcoded 16S rRNA
amplicons. Whole genomic DNA was extracted from each stool
sample and the variable regions 1 and 2 (V1–V2) of the 16S rRNA
gene were amplified using universal primers as described
previously [27]. Using a Roche/454 FLX pyrosequencing
instrument, we generated a dataset consisting of 394,002 high-
quality, classifiable 16S rRNA gene sequence reads (average read
length: 240 bp) with an average of 5,184 reads per samples.
Phylum level analysis of the colonization process revealed that
at 7 days, most communities were comprised of a combination of
members of the phyla Proteobacteria and Firmicutes, with
Firmicutes dominating. Starting at 30 days of life, the abundance
of Proteobacteria was diminishing while that of Actinobacteria was
increasing. By 12 months the communities of both groups of
infants were mainly composed of Firmicutes and Actinobacteria,
while Proteobacteria represented less than 1% of the communities.
At 18 months, Firmicutes were established as dominant members
in more than 90% of the communities sampled (Figure 2A and
Figure 1. Cumulative incidence of AGA antibodies. Percent of
AGA positive subjects enrolled in the study in each intervention group.
* denotes time of gluten introduction, red, group B and blue, group A.
doi:10.1371/journal.pone.0033387.g001
Figure 2. Heatmaps of relative abundance of bacterial phylum in the GI microbiota of samples collected longitudinally from 7 d to
24 months of age in DQ2
+/DQ8
+ infants (color key is indicated on the right). A. Samples are grouped by subjects ID and intervention
groups. B. Samples are grouped by timepoints. Red bars indicate samples from subjects in intervention group B. Missing data point are indicated with
a white vertical line. Stool samples collected from adult subjects that were processed in parallel are included for comparison (from left to right):
subject 69: gluten-free diet for more than 24 weeks and HLA DQ2/8
+; subject 103: HLA DQ2/8
+, subject 67 HLA DQ2/82; subject 86: diagnosed with
CD and HLA DQ2/8
+; subject 34: gluten-free diet for more than 24 months and HLA DQ2/8
+; subject 36: HLA DQ2/82; subject 6: HLA DQ2/8
+; subject
49: HLA DQ2/82.
doi:10.1371/journal.pone.0033387.g002
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with uncharacterized genetic backgrounds [28], all communities of
infants genetically at-risk for CD enrolled in this study were
characterized by a low abundance of members of the phylum
Bacteroidetes (undetectable to 1%). Quantitative real-time PCR
indicated that the total number of 16S rRNA gene copies in the
infants’ GI communities ranged from 10
9 to 10
10 copies per gram
of stool, while Bacteroidetes 16S rRNA gene copies ranged from
10
2 to 10
7 copies per gram of stool (Figure 3). This analysis
confirmed that the relative abundance of Bacteroidetes was low,
averaging three orders of magnitude lower than the total amount
of bacteria, hence falling below the detection level of the
sequencing analysis (represented by the depth of reads sampling,
in this case, 5,184 reads per sample on average). A phylum level
comparison with the study of Palmer et al. [28] who described the
infant gut microbial colonization process in 14 infants up to 1K
years of age, is shown in Figure 4. Unlike in our findings, Palmer
et al, demonstrated that Bacteroidetes is a common member of the
infant GI microbiota after introduction of solid food at 6 months of
age and thereafter (time point C, F and G).
The apparent transition and stabilization trends observed at the
phylum level were not supported when analysis was performed at
the genus level. Instability and high level of inter-individual
variation were evident (Figure S3). The main genera observed in
higher abundance belong to the phylum Firmicutes and were
Streptococcus, Lachnospira, Erysipetotrichae, Lactobacillus, Bryantella and
Enterobacter.
Principal coordinate analysis (PCoA) of UniFrac distances
reveals a high heterogeneity between community compositions
for the first 30 days with communities spread along PC2
(Figure 5A, red spheres and 5B, blue spheres). A directional
pattern was observed in which communities converged over time
toward higher level of similarities at 18 and 24 months along PC1
(Figure 5). At 24 months, GI communities, while not identical
due to the lack of members of the phylum Bacteroidetes, tend to
resemble those of adult subjects (Figure 5, gold spheres). In this
analysis, different trends of convergence are observed for each
intervention group (Figure 5B) after introduction of gluten. At 6
months, gluten introduction along with solid food tends to shift
communities upward along PC2 (Figure 5B, green spheres) and
PC1, while group A GI community compositions evolved
moderately along PC1, with a few communities at 6 and 8
months still more similar to those found at 7 and 30 days
(Figure 5B, red spheres). Using the Metastat software [29], we
showed that the difference between group A and group B infants
at time point C was statistically significant for the phyla Firmicutes
(p-value=0.00192) and Proteobacteria (p-value=0.04588).
Subject 8 belongingto early gluten exposure group B was positive
for AGA and anti-TTG/EMA at 18 and 24 months respectively
and developed CD at 24 months. Interestingly, the GI microbiota
composition of this subject appears to follow an outlier pattern as
indicated on Figure 5 (circled spheres) compared to the other
DQ2
+/DQ8
+ infants. Introduction of gluten at 6 months of age in
this subject triggered a major shift in community composition,
which was comprised essentially of Lactobacillus until about 12
months of age (Figure S3A). Surprisingly, by 18 months of age, the
GI microbial community of subject 8 appears more similar to GI
microbiota of the other infants (Figure 5). Rarefaction curves were
used to evaluate richness (i.e., number of unique bacterial taxa) in a
sample (Figure S4). Interestingly, while most samples show an
increase in richness over time (as shown by increasing slopes with
time), subject 8 shows a dramatic reduction in bacterial richness in
samples collected before the onset of CD (time points C, D and E
corresponding to 6, 8 and 10 months of age).
Figure 3. Quantitative real-time PCR of total 16S rRNA gene copies (red) and Bacteroidetes 16S gene copies (blue) for all samples
analyzed at each time point in triplicate.
doi:10.1371/journal.pone.0033387.g003
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A total of 17 fecal samples from three group A infants and 21
samples from three group B infants were processed for metabolic
profiling by
1H NMR spectroscopy. These infants were selected to
represent each intervention group, most time points and different
outcomes (group B: subject 8: positive for CD autoantibodies and
AGA/IgG; subject 14: negative for CD autoantibodies, but positive
for AGA/IgG; subject 20: negative for CD autoantibodies and
AGA/IgG). Overall, strong signals from lactose, glucose and other
sugars (d=3.2–5.5 ppm) were observed in infants up to 30 days old.
Resonances foracetate(d=1.92 ppm)andsuccinate (d=2.41 ppm)
weresomewhat pronounced as well. Starting at 6 months of age, the
resonance levels of sugars dropped dramatically, while peaks for a
number of amino acids and short chain fatty acids (SCFA) became
more prominent. Figure 6 shows the normalized concentration of
selected metabolites present in stool samples from infants between 7
days to 24 months of age. Acetate levels stayed high during the
whole time period and relative percentages increased after weaning,
whereas sugars levels decreased (Figure 6C). Succinate levels
initially increased after weaning and later dropped after the infants
reached 10monthsofage(Figure6B).Butyratewasalmostentirely
absent in infants less than 6 months old and increased in most of the
infants older than 10 months of age (Figure 6E).
Principal component analysis (PCA) was carried out on the
normalized
1H NMR spectra of the fecal extracts to generate an
overview of the variations between infants in intervention group A
and B. Three principal components were calculated that
accounted for 79% of the variance observed. While no clear
separation of the metabolomes from group A and B was observed,
the samples clustered by ages (Figure 6A). Using loading plot and
NMR spectra analysis, we identified the metabolites responsible
for the clustering (Figure S5). The 7-day and 30-day samples
clustered together mainly because of high sugar contents, while the
metabolomes of samples from infants older than 10 months
clustered together mostly due to the presence of butyrate and
propionate. Interestingly, the samples from 6- to 10-month old
infants mostly clustered separately with higher levels of succinate.
A few exceptions were noted, such as subject 20 (group B - 12
months sample (20F)), which clustered with samples from younger
infants, and subjects 12 and 13 (group A – 8-month samples (12D
and 13D)), which clustered with samples collected from older
infants (Figure 6A). Those were the only differences observed
Figure 4. Heatmap of relative abundance of bacterial phylum of longitudinal samples from DQ2
+/DQ8
+ infants analyzed in this study
and those of Palmer et al. [28] (D), Color keys are indicated on the upper right corner. A. Complete linkage clustering based on the phylum
composition andabundance of GI microbiota. B. Color depicts the study andintervention group of the samples. C. Colors depict the time point at which
the samples were collected. Time points D and E were omitted as no corresponding samples were collected in the Palmer et al. study [28].
doi:10.1371/journal.pone.0033387.g004
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who developed CD at 24 months of age) at time points C (6
months) and D (8 months) were significantly different from those
of the other infants at the same age. The loading plots indicated
that the clustering in these samples was heavily influenced by
higher lactate levels (Figure S5). The normalized lactate content
was plotted against the age of the infants and is shown in
Figure 6D. The lactate signals continued to be higher for subject
8 until 12 months of age before the first detection of positive
antibodies. This period of high lactate signals (6–8 months of age)
corresponds with a higher relative abundance of Lactobacillus spp.,
which dominated the stool microbial community of subject 8 with
88%, 57% and 81% at 6, 8 and 12 months, respectively.
Discussion
We have demonstrated that infants genetically susceptible for
CD (DQ2
+/DQ8
+/DQ2–8
+) in which gluten introduction in their
diet was delayed from 4–6 months of age to 12 months of age
showed a decrease in immune response to gluten and a lower
incidence of CD autoimmunity. Therefore, our results suggest that
a delayed introduction of gluten in the diet of genetically
susceptible infants can at least delay the onset of the disease. This
observation was accomplished by using a prospective clinical study
that included a dietary intervention with randomized and double-
blind allocation to two diet groups (gluten-containing and gluten-
free diets between the ages of 6 months to 1 year). This unique
longitudinal study design allowed for the prospective collection of
biological specimens that included stool samples, as well as
behavioral and diet metadata.
In this study, we tested the effect of early exposure to gluten (6
months of age) or late exposure (12 months of age) on the immune
response to gluten and development of CD autoimmunity in 26
genetically susceptible infants. We showed that delayed exposure
to gluten has a positive effect on prolonging gluten tolerance and
delaying onset of CD autoimmunity. During early childhood,
antibodies can fluctuate between positive and negative, in line with
the fluctuation seen in the incidence of AGA IgG in this study
Figure 5. Principal Coordinate Analysis (PCoA) of unweighted UniFrac distances between samples. A. Samples are colored by time
points, red, 7 d and 30 d, green, 6 m and 8 m, light blue, 10 m and 12 m, dark blue, 18 m and 24 m. B. Samples are colored by intervention groups.
Group A: red, Group B: green. Blue: 7 d and 30 d time points prior to diet intervention. A and B: Gold, adult controls: subject 34 gluten-free diet for
over 24 weeks and HLA DQ2/8
+; subject 67 HLA DQ2/82; subject 103 HLA DQ2/8
+; subject 86; diagnosed with CD and HLA DQ2/8
+.
doi:10.1371/journal.pone.0033387.g005
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1H-NMR metabolomics analysis. A. PCA analysis of metabolomic profiles (A). Relative concentration of major metabolites measured
from stool NMR profiles in selected subjects over the 24-month study period (B–F). B. Succinate; C. Acetate; D. Lactate; E. Butyrate and F. Propionate.
The chemical shift (ppm) value of each metabolite is indicated above each panel.
doi:10.1371/journal.pone.0033387.g006
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because, despite the significant progress made in understanding
the adaptive immunological aspects of CD pathogenesis, the early
steps following intestinal mucosal exposure to gliadin that lead to
the loss of tolerance and the development of the autoimmune
process are still largely unknown. Increasing evidence in the
literature seems to suggest a dysfunctional cross talk between
innate and adaptive immunity as the key pathogenic element in
the autoimmune process of the disease [31]. Recent retrospective
studies also suggest that this dysfunctional cross talk could be
influenced by the timing of gluten introduction into the diet, but
more importantly, the studies suggest a potential role of the GI
microbiota composition in subjects genetically susceptible to CD
[32].
CD incidence is markedly increasing [13,33], along with other
immune-mediated disorders such as inflammatory bowel diseases
(IBD), asthma or atopy [34]. The rapidity of the increase in disease
rates could never be solely explained by changes in genetic make-
up [35]. This hypothesis is supported by our recent prospective
study on a single American cohort followed since 1974 indicating
that CD autoimmunity in these subjects doubled between 1974 (1
of 501 subjects) and 1989 (1 of 219 subjects), thus excluding the
genetic component as the cause of this increased prevalence [36].
Rather, alterations in host-commensal microbial interactions could
have a pivotal role in the development of autoimmune disorders
by triggering increased immune stimulation, epithelial dysfunction
and enhanced mucosal permeability [37,38]. The colonization of
the GI tract, i.e. the succession of microbial communities that are
established in the GI tract starting at birth, has been identified as a
key factor influencing the risk of autoimmune and food-related
diseases [39]. The involvement of intestinal colonization in the
maturation of immune responses is well characterized in animal
models, showing that both the intestinal-associated immune system
and systemic immunity mature upon stimulation by the GI
microbiota. Germ-free animals show extensive defects in the
development of gut-associated lymphoid tissues and in antibody
production, and have fewer and smaller Peyer’s patches and
mesenteric lymph nodes [40,41]. Furthermore, it has been shown
that germ-free animals have impaired development and matura-
tion of isolated lymphoid follicles [42]. Recent studies also suggest
that intestinal bacteria interact with the mammalian immune
system to direct the differentiation of both pro- and anti-
inflammatory T cell populations [43]. Because the microbiota
has marked influences on the immune system, we have
hypothesized that deviations from the ‘‘normal’’ development of
the microbiota may alter the outcome of immune development
and potentially predispose individuals to inflammatory diseases.
Our longitudinal study design allowed us to characterize the GI
microbial colonization processes from 7 days to 24 months of age
in DQ2
+/DQ8
+ infants from two intervention groups. One of the
major finding of our study is that unlike in infants without a family
history of CD and without genetic susceptibility to CD [28], the
GI tract microbiota in DQ2
+/DQ8
+ infants appears to be lacking
significant numbers of member of the phylum Bacteroidetes. The
GI tract microbiota in these DQ2
+/DQ8
+ infants does not
stabilize nor resembles adult microbiota at 1 year of age, and this
characteristic remains at 24 months of age. A comparison with the
study of Palmer et al. [28] highlights these major differences. In
non-susceptible infants, the GI microbiota composition changes
with different life stages, the most important of which is the
introduction of solid food around 6 months of age. Overall the
microbial ecosystem in each healthy baby achieves stability
converging toward a profile more similar to that of an adult in
the first year of life [28] with the level of Bacteroidetes ranging
from a few percent to over 50% by 1 year of age. A recent paper
by Koenig et al. [44] who described the GI colonization process in
one infant for 2.5 years, further support the results of Palmer et al.
[28]. In that study, Bacteroidetes comprised between 40 and 60%
of the communities from 6 months to 2.5 years of age and the GI
communities appeared to stabilize at 1 year of age [44]. It is
evident that the colonization process in these infants with a higher
abundance of Proteobacteria and Bacteroidetes throughout the
first year of life and a lower abundance of Firmicutes, is
dramatically different from those in the present study who are
DQ2
+/DQ8
+ and with a family risk of CD. A complete clustering
analysis of GI microbial communities from non-susceptible infants
and the communities in this study revealed two major groups
(Figure 4) separating infants by HLA genetic background and
family history of CD. The result is highly influenced by the high
abundance of Firmicutes and low abundance of Bacteroidetes in
infants genetically susceptible for CD (mostly time points D, E, F
and H [.6 months]), and by the high abundance of Proteobac-
teria in the earlier time points in the Palmer et al. study [28].
The ratio of Firmicutes over Bacteroidetes is known to vary
throughout the lifespan. The ratio is lower in the first year of life,
becomes higher in adulthood, and decreases in elderly [45].
Bacteroidetes have also been found to delineate profound
differences between African and European children [46], with
significantly higher levels of Bacteroidetes in African than
European children. While certainly influenced by diet, a higher
abundance of Bacteroidetes in African children appear to be
protective against pathogens and other gastrointestinal diseases
[46] and indicates a potential impact of the Western diet on the
colonization and the establishment of the GI microbiota in Europe
and other developed countries. The beneficial role of members of
the phylum Bacteroidetes, including Bacteriodes fragilis, has been
previously demonstrated [47,48]. B. fragilis has been shown to
establish a cross-talk between the GI microbiota and the intestinal
epithelium [49]. B. fragilis, through the production of a
polysaccharide capsule, directly induces the development of
FoxP3+ regulatory T cells, which in turn produces anti-
inflammatory cytokine directly in the gut [49]. The lack of
Bacteroidetes could represent a major predisposing deficiency in
infants genetically susceptible for CD, since it has been reported
that quantitative and/or qualitative defects of FoxP3+ regulatory
T cells affect immune tolerance surveillance and, therefore may
lead to the autoimmune response typical of CD [50].
Our findings of decreased Bacteroidetes abundance in children
at risk of CD are at odds with previous reports showing higher
Bacteroidetes representation in CD children [23,51]. However,
substantial differences between our study design and the approach
used by other investigators in regards to microbiota analysis
(fluorescent in situ hybridization coupled with flow cytometry), age
of children studied (older children), and clinical characteristics
(children already affected by CD) make previous findings not
directly comparable to our results. Indeed, to our knowledge, our
study is the first prospective report on infants at risk of CD that
analyzes the microbiota dynamic over time starting from birth,
using state-of-the-art microbiome 16S rRNA short amplicon
pyrosequencing combined with quantitative PCR and
1H NMR
spectroscopy. The key finding of our report is the lack of
maturation of the gut microbiota within the first 2 years of life in
infants at risk of CD characterized by a relative absence of
Bacteroidetes and a parallel high abundance of Firmicutes. It is
important to note that differences in stool sampling and storage,
DNA extraction and purification methods, 16S rRNA gene PCR
primer pairs, and sequencing methods between all studies,
including this and the Palmer et al. study [28] could potentially
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GI microbial community. However, it is unlikely that the DNA
extraction method used in this study is responsible for the observed
low abundance of Bacteroidetes, as high abundance of this phylum
was detected in stool samples (Figure 2) from adult subjects (HLA
DQ2/8- and some HLA DQ2/8
+ on gluten free diet for more
than 24 months). Furthermore, the method is commonly used to
extract stool samples in our laboratory and members of the
phylum Bacteroidetes and other phyla are often identified (data
not shown).
Metabolomic profiling of selected subjects and samples revealed
that few metabolites appeared important and accompanied the
succession of the microbial taxa colonizing the GI during the first
two year of life. The GI metabolome during the first 6 months of
life reflects the infants’ diet of exclusively milk comprised mainly of
polysaccharides and other sugars. This unique metabolic profile is
very similar in all infants. However, once solid food is introduced
at 6 months of age, a major shift occurs and the SCFA succinate,
acetate, propionate and butyrate are found in the feces. By 24
months, butyrate and acetate are the main SCFA present in the
metabolome of these infants. A recent study found Bacteroidetes
associated with the presence of butyrate, and acetate and most
strongly with propionate, while Firmicutes was negatively
associated with these SCFAs [44]. The role of these SCFAs is
thought to be protective and the results of the breakdown of
complex plant polysaccharides by Bacteroidetes [52]. Propionate
was not found in high level in the feces of the infants studied
compared to other published studies [44]. This finding correlates
with the concordant lack of Bacteroidetes in the GI microbiota of
infants genetically susceptible for CD. One can envision that the
high abundance of Firmicutes and the low abundance of
Bacteroidetes in these infants results in lower levels of SCFAs in
the GI tract and a diminished GI health and/or a predisposition
for CD or other autoimmune diseases. More quantitative methods
and a higher number of subjects would be needed to confirm this
finding. The metabolic profiles are consistent across the infants
and cluster by age (Figure 6A). This finding supported the
concept that while GI microbiota may differ in microbial species
composition and abundance, they conserve a functional core,
whether it is as conserved gene content [53] or as observed in this
study in conserved metabolic output. Our metabolomic analysis
did not reveal any consistent differences between infants from each
dietary intervention group (Figure 6). However, because one of
the infants (subject 8) was diagnosed with CD at 24 months, we
had the opportunity to prospectively examine both the GI
microbiota colonization process and its associated metabolome.
Interestingly, between 6 and 12 months of age, the metabolome of
subject 8 contained high levels of lactate (Figure 6D), which
correlated with the presence of high levels of Lactobacillus spp. in
the GI microbiota (Figure S3). Two more subjects showed
elevation of lactate in their metabolome profile. Subject 15 (group
A) showed elevated and sustained lactate levels within an interval
period similar to subject 8 (from 6 to 10 month of age)
(Figure 6D). Interestingly, subject 15 developed type 1 diabetes
(T1D), another autoimmune disease, at 22 months. The second
subject with elevated lactate (subject 20, group B) showed only a
very transient increase in lactate at age 8 months which returned
to baseline levels similar to other infants by 10 months of age
(Figure 6D). Based on these results, it is tantalizing to hypothesize
that a decrease in Lactobacillus spp., with a subsequent decrease in
lactate production during a crucial time of maturation of mucosal
immunity functions (between 6 and 12 months of age) can leads to
loss of tolerance to non-self antigens (gluten in case of CD,
unknown antigen(s) in case of T1D) in genetically susceptible
individuals. Larger studies with more cases are necessary to
support this hypothesis.
Subject 8 also experienced reduced bacterial richness during the
intervention period compared to the other infants, which showed
increased richness with time (Figure S4). While this was observed
in only one infant, it introduces the possibility of discovering
potential biomarkers that could be predictive to the development
of autoimmunity in CD; a longitudinal study design is essential to
achieve this goal.
In summary, infants genetically susceptible for CD may benefit
from delayed exposure to gluten from 6 months of age to at least
12 months of age. While the molecular mechanisms underlying the
benefit are yet unknown, it might be related to a lack of maturity
of the GI microbiota in these infants, and we hypothesize that the
introduction of gluten in an immature GI microbiota could trigger
or accelerate the development of autoimmunity. By combining
16S rRNA gene short amplicon pyrosequencing, quantitative
PCR and
1H NMR spectroscopy to analyze the microbiota of
infants with genetic predisposition for CD over the first two years
of life, we have characterized the GI colonization process and its
metabolic output in infants genetically susceptible for CD. The
data presented here, while derived from a relatively small number
of subjects, suggest significant differences between the developing
microbiota of infants with a genetic predisposition for CD and
those from infants with a non-selected genetic background.
Furthermore, the metabolic output of the GI microbiota in these
infants while similar to one another within age groups might reflect
a potential dysbiosis of the GI microbiota and lead to less than
optimal cross-talk with the host to promote health. Interestingly,
one of the infants in the study was diagnosed with CD at 24
months of age. The retrospective analyses of the GI microbiota
and metabolomic data suggest that potential specific biomarkers
might be identified that would be predictive for autoimmune
development in subjects genetically at risk, possibly leading to the
development of potential interventions during the pre-clinical
phase of the disease to arrest the loss of tolerance to gluten and,
therefore, to prevent the onset of CD autoimmunity.
Materials and Methods
Study design and sample collection
The study was prospective and included a dietary intervention
with randomized and double-blind allocation to two diet groups.
Infants with first-degree relatives diagnosed with biopsy-proven
CD were enrolled between 2005 and 2009 (Figure S1). The
HLA-DQ2/DQ8 determination was performed soon after birth,
when possible on cord blood, or at the time of recruitment.
Positive subjects for HLA-DQ2 and/or DQ8 genotype were
included in the interventional study. Data on clinical and dietary
history were recorded including type of delivery, gestational age,
birth weight, type of feeding, antibiotic use and neonatal
complications. All infants received exclusive milk feeding during
the first 6 months of life. From weaning (6 months of age) to 12
months all recruited infants were on the same basic gluten-free diet
and were randomly assigned to two different arms. In group A,
infants received a daily supplement consisting of purified corn
starch (3 g from age 6–9 months and 5 g from age 9–12 months),
while group B infants received a daily supplement consisting of
purified gluten from hexaploid wheat (3 g from age 6–9 months
and 5 g from age 9–12 months). After 12 months of age all
children (group A and B) were allowed an appropriate unrestricted
diet and were followed every 6 months up to 24 months. From
weaning to 12 months, the clinical data, the adherence to the
dietary protocol, and the amount of intervention food supplement
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(AGA) IgA and IgG antibodies, anti-tissue transglutaminase (tTG)
IgA and IgG antibodies, anti-endomysial (EMA) IgA antibodies)
and total IgA measurement were performed at the time of
recruitment and at each 6-month follow up visit. Stool samples
were collected at 7 and 30 days and at6, 8, 10, 12, 18 and 24
months of age. Infant stool samples were obtained by the parents
using stool collection vials and were immediately stored in home
freezers at 220uC and then transported frozen to the laboratory
within 24 h where the samples were stored at 280uC until
processed.
The University of Maryland School of Medicine Institutional
Review Board approved the study protocol and written informed
consent was obtained from the parents of all children enrolled.
Subject enrollment and retention
A total of 47 at-risk infants were screened. After HLA typing, 34
(72%) infants were positive for HLA-DQ2 and/or DQ8 genotype
and, therefore, met the enrolling criteria. The families of 4 of these
infants refused randomization. The remaining 30 infants were
blindly randomized to the two groups once they reached weaning
age (Figure S1). Since this was an ongoing enrolling study, more
patients were enrolled in group B (early exposure to gluten, n=17)
than in group A (late exposure to gluten, n=13) to counterbalance
for non-compliance to the feeding intervention (n=3) or loss at
follow up (n=1) of 4 infants assigned to group B (Figure S2).
HLA typing
The HLA II alleles (DQA1*0201, DQA1*03, DQA1*05,
DQB1*02, DQB1*0302, DRB1*03, DRB1*04 and DRB1*07)
were typed using the DiaGene kit (Palermo, Italy) at the University
of Maryland School of Medicine, Center for Celiac Research.
PCR amplicons were resolved by electrophoresis on 2% agarose
gel and stained using ethidium bromide.
CD serology
Both anti-tTG and anti-AGA antibodies were determined by
ELISA assay using an ImmunoCAP 100 instrument (Phadia,
Portage MI) and as recommended by the manufacturer. Values
higher than 7.0 AU were considered positive for all assays. EMA
was detected by indirect immunofluorescence assays (Scimedx,
Denville, NJ) using monkey esophagus as substrate and as
recommended by the manufacturer. Values above 1:10 were
considered positive.
Definition of gliadin immune response and CD
autoimmunity
Gliadin immune response was defined as the presence of IgG
and/or IgA anti-AGA antibodies above the 7.0 AU. CD
autoimmunity was defined as the presence of tTG antibodies
higher than 7 AU and subsequent positivity to EMA, with or
without AGA positivity.
Total DNA extraction from stool
Frozen fecal material (150 mg) was mixed with 1 ml of 0.05 M
potassium phosphate and transferred to a FastPrep Lysing Matrix
B tube (Bio 101). Cell lysis was initiated by adding 5 ml lyzozyme
(10 mg/ml), 15 ml of mutanolysin (11,700 U/ml; Sigma-Aldrich,
St. Louis, MO) and 5 ml of lysostaphin (4,000 U/ml in sodium
acetate; Sigma-Aldrich). Following a 30 min incubation at 37uC,
10 ml proteinase K (20 mg/ml), 50 ml 10% SDS, and 2 ml RNase
A (10 mg/ml) were added to the mixture and incubated for
45 min at 55uC. Microbial cells were further lysed by mechanical
disruption using a bead beater (FastPrep instrument, Qbiogene,
Montreal) set at 6.0 m/s for 40 sec. The lysate was processed using
the ZYMO Fecal DNA extraction kit (ZYMO Research, Irvine,
CA) omitting the lysis steps and according to the manufacture’s
recommendation. The samples were eluted with 100 ml of hot
molecular biology-grade water (56uC) and quantified using
Picogreen.
Pyrosequencing of barcoded 16S rRNA gene amplicons
The two universal primers 27F and 338R were used for PCR
amplification of the V1–V2 hypervariable regions of the 16S
rRNA gene [54]. The 338R primer included a unique sequence
tag to barcode each sample. The primers were as follows: 27F - 59-
GCCTTGCCAGCCCGCTCAGTCAGAGTTTGATCCTGG-
CTCAG-39 and 338R - 59- GCCTCCCTCGCGCCATCAG-
NNNNNNNNCATGCTGCCTCCCGTAGGAGT-39, where
the underlined sequences are the 454 Life SciencesH FLX (454
Life Sciences, Branford, CT) sequencing primers B and A in 27F
and 338R, respectively, and the bold font denotes the universal
16S rRNA primers 27F and 338R. The 8-bp barcode within
primer 338R is denoted by 8 Ns. 16S rRNA genes were amplified
in 96 well microtiter plates using AmpliTaq Gold DNA
polymerase (Applied Biosystems, Carlsbad, CA), and 50 ng of
template DNA in a total reaction volume of 50 ml. Reactions were
run in a PTC-100 thermal controller (MJ Research, Hatboro, PA)
using the following cycling parameters: 5 min of denaturation at
95uC, followed by 20 cycles of 30 sec at 95uC (denaturing), 30 sec
at 56uC (annealing) and 90 sec at 72uC (elongation), with a final
extension at 72uC for 7 minutes. Negative controls without a
template were included for each barcoded primer pairs. The
presence of amplicons was confirmed by gel electrophoresis on a
2% agarose gel and staining with SYBRGreen. PCR products
were quantified using a GelDoc quantification system (BioRad,
Hercules, CA) and equimolar amounts (,100 ng) of the PCR
amplicons (96 samples) were mixed in a single tube. Amplification
primers and reaction buffer were removed by processing the
amplicons mixture with the AMPure Kit (Agencourt, Beverly,
MA). The purified amplicon mixtures were sequenced by 454
FLX pyrosequencing using 454 Life SciencesH primer A by the
Genomics Resource Center at the Institute for Genome Sciences,
University of Maryland School of Medicine using protocols
recommended by the manufacturer and as amended by the
Center.
Sequences were binned by samples using the sample-specific
barcode sequences and trimmed (removal of the barcode and
primer sequences). We used criteria previously described to assess
the quality of sequence reads. Briefly, to pass, a sequence read had
to (a) include a perfect match to the sequence tag (barcode) and the
16S rRNA gene primer; (b) be at least 200 bp in length; (c) have
no undetermined bases; and (d) have at least a 60% match to a
previously determined 16S rRNA gene sequence. Phylum and
genus level taxonomic assignments were performed using the RDP
Classifier [55]. For the RDP classifier, we required .50%
confidence for all calls. Trimmed pyrosequence reads were
processed with the CloVR-16S pipeline [56] of the Cloud Virtual
Resource (CloVR) [57]. CloVR-16S integrates component of the
QIIME [58] and Mothur [59] packages to align reads with Pynast
[60], construct phylogenetic trees with FastTree2 [61], calculate
UniFrac distances, and generate PCoA plots based on UniFrac
distances. OTUs were computed using the pick_otus and
pick_rep_set workflow scripts in QIIME. High-quality sequences
were first clustered into OTUs using UCLUST [62] with a 97%
identity threshold. The most abundant sequence in each OTU was
then selected as its representative member. Rarefaction curves
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UCLUST as input.
Sequences have been deposited in the Short Read Archive
under accession number ###### (pending).
Quantitative PCR assay
A separate real-time quantitative PCR (qPCR) assay was used to
amplify and quantify rRNA gene copy number from total bacteria
and those belonging to the phylum Bacteroidetes. Total pan-
bacterial 16S rRNA gene qPCR was performed using primers 59-
CCTACGGGDGGCWGC-39, ‘5-GGACTACHVGGGTMTC-
TAATC-39 as forward and reverse primers respectively and
6FAM-CAGCAGCCGCGGTA-MGBNFQ as TaqMan probe.
Bacteroidetes qPCR were performed using primers 59-AACGC-
TAGCTACAGGCTTAACA-39,5 9-ACGCTACTTGGCTGG-
TTCA-39, and 6FAM-CAATATTCCTCACTGCTGCCTCC-
CGTA-TAMRA, for the forward, reverse and probe primers
respectively [63]. For both qPCR assays, each 20-ml reaction
contained 1X Invitrogen (Grand Island, NY) qPCR SuperMix,
1.8 mM of each primer, 0.2 mM of the probe, and 1 ml of extracted
DNA. The thermal cycling program consisted of 50uC for 3 min
for uracil-N-glycosylase activation, 95uC for 5 min for denatur-
ation, followed by 45 cycles of 95uC for 30 s, 55uC for 30 s and
60uC for 1 min. Reactions were carried out in a Prism 7900HT
Sequence Detection System (Applied Biosystems). Ten-fold serial
dilutions of known quantities of cloned 16S rRNA genes and
Bacteroidetes targets were used to generate standard curves
(ranging from 10
1 to 10
8 gene copies/ml). Absolute 16S rRNA
genes abundance was calculated based on the standard curves
using SDS software version 2.1 (Applied Biosystems). The total
copy number of 16S rRNA genes was normalized to gram of stool
sample processed. All of the reaction mixtures were run in
triplicate and each plate included three no-template controls.
Comparative analysis with previous studies datasets
The study by Palmer et al. [28] used a microarray platform to
evaluate the present/absence and abundance of microbial taxa.
The relative proportion of each phylum in the datasets was
calculated by normalizing the raw intensity values for each phylum
to the total amount of intensity for all phyla. This procedure was
performed for each samples and provided the relative percent
abundance of phyla in each samples.
1H-Nuclear Magnetic Resonance Spectroscopy (NMR)
spectroscopy and metabolomic analysis of fecal samples
For each sample, 100 mg of frozen fecal sample was placed into
a 1.5 ml centrifuge tube and 1.0 ml of deuterated water (D2O)
added as extraction solvent. The sample was homogenized by
vortex mixing for 1 min and stored on ice for 10 min. After
centrifugation (10 min, 13,000 rpm at 4uC), the supernatant was
collected and filtered through a 0.45 mm MCE filter (Fisherbrand,
Pittsburg, PA) to remove particulates. The filtered fecal solutions
were stored at 280uC prior to analysis. As a control to determine
whether any contamination may have been introduced by
filtration, a sample containing only deuterated water was also
filtered using the same procedure.
NMR was used to monitor the metabolite profiles. Two hundred
mloftheresultingfecalextractwasdilutedwithD2O yielding a 500 ml
sample containing 50 mM phosphate buffer at pH 7.0 and 30 mM
sodium 3-(trimethylsilyl) propionate -2,2,3,3-d4 as internal chemical
shift reference. The resulting solution was mixed by vortex and then
centrifuged at 13,000 rpm for 2 min and transferred to a 5 mm
NMR tube. All
1H-NMR experiments were carried out at 25uCo na
Varian AS500 spectrometer operating ata protonNMR frequency of
499.75 MHz. One-dimensional spectra were recorded using stan-
dard tnnoesy pulse sequence. Each spectrum consisted of 128
transients with a spectral width of 12 ppm and relaxation delay of
5.0 s. All free induction decays were Fourier transformed with an
exponential function equivalent to a 0.3 Hz line-broadening factor
and the spectra were zero filled to 32K points. The resulting spectra
were manually phased and baseline corrected using ACDLABS
(version 10.0, Advanced Chemistry Development, Inc., Toronto,
ON, Canada). For
1H-NMR signal assignment purposes, two-
dimensional (2-D) J-resolved spectroscopy [64] and total correlation
spectroscopy (TOCSY) [65] NMR spectra were acquired for two
selectedsamples.J-resolvedspectrawerecollectedusing128scansper
32 increments with 5000 Hz spectral width in F2 and 36 Hz in F1.
The TOCSY spectra were recorded with a data matrix of 20486128
with spectral width of 5000 Hz in F2 and F1. Sixty-four scans were
acquired and a mixing time of 80 ms was used. All 2-D NMR data
were processed with the software package NMRPipe [66].
For PCA analysis, the
1H-NMR spectra were reduced to 119
integrated regions of varied width corresponding to the region of
d=0.40–8.50 ppm using intelligent bucketing from ACD Labs
(Toronto, ON, Canada). The region from d=4.7–5.0 ppm was
excluded from the analysis to avoid the phasing effects of the pre-
saturation of the residual water signal. Normalization of the
integrals to the total sum of the spectrum was carried out on the
data prior to principle component analysis (PCA) to allow for
differences in signal-to-noise. PCA was performed with the
SIMCA-P software (version 10.0, Umetrics, Sweden). The data
were pre-processed by Pareto scaling.
The relative concentration of metabolites was represented by
the integral values of their peak regions. To make the individual
peak areas comparable between samples, normalization of the
total integral sum of the whole spectrum (set as 1000) was carried
out. The values were then divided by the number of protons of the
corresponding peak. Figure 6 shows the relative concentration of
selected metabolites present in the samples obtained from infants
age 7 days to 24 months.
Supporting Information
Figure S1 Schematics of the clinical study design. GFD: Gluten-
Free Diet.
(TIF)
Figure S2 Flow-chart depicting infants enrolled in the study and
those that were selected for microbiota characterization.
(TIF)
Figure S3 Heatmaps of relative abundance of bacterial genera
in the GI microbiota of samples collected longitudinally from 7 d
to 24 months of age in DQ2
+/DQ8
+ infants (color key is indicated
on the right). A. Samples are grouped by subjects ID and
intervention groups. B. Samples are grouped by time points. Red
bars indicate samples from subjects in intervention group B. Taxa
are ordered from most abundant to least abundant. ‘‘Unclassifi-
able reads’’ represent a set of reads for which statistical support
was not achieved by the RDP classifier to be assigned to a specific
genus.
(TIF)
Figure S4 OTU-level rarefaction curves for each subject and
time point. Infants in group B are indicated by a red bar. Time
points are indicated by different colored lines.
(TIF)
Figure S5 Loading scatter plot associated with the PCA metabo-
lomics profiles analysis presented in Figure 6A. Metabolites that
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